Abbvie Inc (ABBV)

$229.31 +0.82 (0.36%)
Market Cap 405.28B
Revenue (ttm) 56.33B
Net Income (ttm) 4.28B
EPS (ttm) N/A
PE Ratio 24.18
Forward PE 15.85
Profit Margin 7.59%
Debt to Equity Ratio -26.45
Volume 3,336,800
Avg Vol 5,515,752
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 72%
Beta 0.36
Analysts Strong Sell
Price Target $245.81

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
MoneyGroupLLC
MoneyGroupLLC Jan. 3 at 9:54 PM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 23 2026 Buy in Price: $4.25 - $4.65 Sell Price: $6.71 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/pricing
0 · Reply
foghornL
foghornL Jan. 3 at 3:54 AM
$ABBV
0 · Reply
PaulBurke55
PaulBurke55 Jan. 2 at 11:28 PM
$SHOP $AVGO $BTC.X $ABBV $TSLA Prices are skyrocketing.
0 · Reply
GoodTidings
GoodTidings Jan. 2 at 5:55 PM
$SLS $ABBV $MRK $PFE just show your cards so Stergiou can determine who is really seriously engaged to share this great succes and paradigm shift in cancer treatment!!! 😎😎😎
1 · Reply
JFais
JFais Jan. 2 at 2:26 PM
$ABBV $IRWD Interestingly enough, Linzess is a pretty important drug within the Parkinson's community (will be thankful when it goes generic 2029 to 2030, otherwise is something like $500 out of pocket at least for us) Up to 80% of patients with Parkinson's disease experience constipation at some point (slowing GI motility makes difficult for food to move through the digestive tract) Might not sound like a big deal until you experience first-hand as patient or caregiver (can lead to loss of appetite, losing lots of weight and then quality of life falls off pretty quick followed by other more serious complications) Of all the options out there like Miralax (some patients won't want to drink 1-2 glasses daily of powder mixed in), Linzess offers the ease of 1 pill/day (starts working within a few days to a week) Sometimes we forget how important convenience is (makes caregiver's life that much easier)
0 · Reply
HerbertSowell1052
HerbertSowell1052 Jan. 2 at 1:57 PM
$ABBV defensive name with steady demand Nice balance if market chops
0 · Reply
ZacksResearch
ZacksResearch Jan. 2 at 11:45 AM
$ABBV's neuroscience segment is a game-changer — here's why it's pivotal for growth! 🚀 AbbVie expects a 19% rise in neuroscience sales for 2025, driven by strong performers like Botox Therapeutic and Vraylar, plus notable contributions from Vyalev. With pipeline expansion and recent acquisitions, the company is set to bolster its position further. Discover the full growth strategy here 👉 https://www.zacks.com/stock/news/2811202/heres-how-abbvies-neuroscience-portfolio-is-aiding-top-line-growth?cid=sm-stocktwits-2-2811202-body-27078&ADID=SYND_STOCKTWITS_TWEET_2_2811202_BODY_27078
0 · Reply
N0Bounds
N0Bounds Jan. 2 at 9:26 AM
$S $GE $UAA $ABBV $UAMY 2
0 · Reply
TalkMarkets
TalkMarkets Jan. 1 at 3:00 PM
Johnson & Johnson Near Year High $JNJ Also $ABBV $BSX $HALO https://talkmarkets.com/content/stocks--equities/johnson--johnson-near-year-high?post=547778&userid=166882
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 1 at 4:03 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 23 2026 Buy in Price: $4.60 - $4.95 Sell Price: $7.54 Profit : +64% (Turn every $1 into $1.64) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
Latest News on ABBV
No data available.
MoneyGroupLLC
MoneyGroupLLC Jan. 3 at 9:54 PM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 23 2026 Buy in Price: $4.25 - $4.65 Sell Price: $6.71 Profit : +58% (Turn every $1 into $1.58) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/pricing
0 · Reply
foghornL
foghornL Jan. 3 at 3:54 AM
$ABBV
0 · Reply
PaulBurke55
PaulBurke55 Jan. 2 at 11:28 PM
$SHOP $AVGO $BTC.X $ABBV $TSLA Prices are skyrocketing.
0 · Reply
GoodTidings
GoodTidings Jan. 2 at 5:55 PM
$SLS $ABBV $MRK $PFE just show your cards so Stergiou can determine who is really seriously engaged to share this great succes and paradigm shift in cancer treatment!!! 😎😎😎
1 · Reply
JFais
JFais Jan. 2 at 2:26 PM
$ABBV $IRWD Interestingly enough, Linzess is a pretty important drug within the Parkinson's community (will be thankful when it goes generic 2029 to 2030, otherwise is something like $500 out of pocket at least for us) Up to 80% of patients with Parkinson's disease experience constipation at some point (slowing GI motility makes difficult for food to move through the digestive tract) Might not sound like a big deal until you experience first-hand as patient or caregiver (can lead to loss of appetite, losing lots of weight and then quality of life falls off pretty quick followed by other more serious complications) Of all the options out there like Miralax (some patients won't want to drink 1-2 glasses daily of powder mixed in), Linzess offers the ease of 1 pill/day (starts working within a few days to a week) Sometimes we forget how important convenience is (makes caregiver's life that much easier)
0 · Reply
HerbertSowell1052
HerbertSowell1052 Jan. 2 at 1:57 PM
$ABBV defensive name with steady demand Nice balance if market chops
0 · Reply
ZacksResearch
ZacksResearch Jan. 2 at 11:45 AM
$ABBV's neuroscience segment is a game-changer — here's why it's pivotal for growth! 🚀 AbbVie expects a 19% rise in neuroscience sales for 2025, driven by strong performers like Botox Therapeutic and Vraylar, plus notable contributions from Vyalev. With pipeline expansion and recent acquisitions, the company is set to bolster its position further. Discover the full growth strategy here 👉 https://www.zacks.com/stock/news/2811202/heres-how-abbvies-neuroscience-portfolio-is-aiding-top-line-growth?cid=sm-stocktwits-2-2811202-body-27078&ADID=SYND_STOCKTWITS_TWEET_2_2811202_BODY_27078
0 · Reply
N0Bounds
N0Bounds Jan. 2 at 9:26 AM
$S $GE $UAA $ABBV $UAMY 2
0 · Reply
TalkMarkets
TalkMarkets Jan. 1 at 3:00 PM
Johnson & Johnson Near Year High $JNJ Also $ABBV $BSX $HALO https://talkmarkets.com/content/stocks--equities/johnson--johnson-near-year-high?post=547778&userid=166882
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 1 at 4:03 AM
Enter: $ABBV Calls Strike Price: $230 Expiry Date: JAN 23 2026 Buy in Price: $4.60 - $4.95 Sell Price: $7.54 Profit : +64% (Turn every $1 into $1.64) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
N0Bounds
N0Bounds Dec. 31 at 10:15 PM
SNSE is the Next big Retail Squeeze!! $KGC $ABBV $TME $SFM $SG 2
0 · Reply
Longbuy1
Longbuy1 Dec. 31 at 9:45 PM
$SLS $PFE $MRK $ABBV ABBV MRK PFE one of your companies is going to buy SLS for 10bil, shares will just converted. Float is 217M with all warrants exercised. Go buy some discounted shares. $GME you can meme SLS now market cap is about 500M. Easy 20-30 bagger that's the floor.
0 · Reply
Longbuy1
Longbuy1 Dec. 31 at 7:13 PM
$SLS where only 41$ short of target value 45$. Question is when $PFE $ABBV $MRK buys us. $GME meme people can still jump in for a 20x bagger.
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 31 at 6:58 PM
$SLS $ABBV bought $IMGN for $10.1B based on this data 16.46Month MOS in Platinum Resistant Ovarian Cancer Gps + Keytruda $MRK achieved a better Phase 2 Result - 18.4 Month MOS ... Gps + Keytruda achieved a better MOS than a drug bought for $10.1B ... so, What is Gps Worth to MERCK, just for this Advanced Ovarian Cancer Setting?
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 31 at 6:29 PM
$SLS $ABBV $IMGN $MRK Dr. Julie Cohen Co-Authored this Gps Keytruda Phase 2 Trial Publication - and said MRK would like to Conduct a Phase 3 Trial for Gps + Key in PROC and that Gps would be even more effective in a Maintenance Setting... The entire MRK team, has been waiting for the GPS P3 Results - just like all of us - and know they will be in a Bidding War once the Results are announced, if not Sooner.
0 · Reply
DennisFrank550
DennisFrank550 Dec. 31 at 4:50 PM
$ASML $ABBV $BAC $COST $AMD Looking forward to more updates
0 · Reply
GoodTidings
GoodTidings Dec. 31 at 3:59 PM
$SLS Take into account a $GME scenario here... Some party is taking uncontrolled short risk here!!! It's unjustifiable and not rational to hold or extend your short position at an obvious and successful end period of a trial with the realistic BO bid wat breaking out between $ABBV , $MRK and $PFE 😎😎😎
0 · Reply
HerbertSowell1052
HerbertSowell1052 Dec. 31 at 1:39 PM
$ABBV pharma staying bid defensive money parked here
0 · Reply
Juhanialainen
Juhanialainen Dec. 31 at 10:02 AM
$SLS Hey $ABBV – let’s make it $80 per share and call it a day. Happy new year!
3 · Reply
GoodTidings
GoodTidings Dec. 30 at 11:38 PM
$SLS Can we say that ex Pfizer part of Sellas board puts $ABBV behind in case the BO war takes off... Is the time ticking for $ABBV or does board membership not have any influence on BO outcome?!!! 🤔🤔🤔
0 · Reply
rpc630
rpc630 Dec. 30 at 8:21 PM
$SLS $ABBV $BMY $RHHBY The Kennedy Woman probably was on this treatment. God rest her soul 🙏
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Dec. 30 at 8:16 PM
$SLS Daily Reminder: AZA+VEN the BAT - Best Available Treatment for SLS Phase 3 Control Arm Patients RECENTLY FAILED 3 Large Phase 3 Trials: VIALE-M FAILED in AML CR1 Maintenance VIALE-T FAILED in AML Post Stemcell Maintenance VERONA FAILED in MDS/AML Precursor - ALL FAILED DUE TO TOXicity Key Fact: $ABBV $BMY $RHHBY who own Azacitidine and Venetoclax - - these 3 Large A** Pharma, Know Right Now, Gps is wholly responsible for the Miraculous Survival of these Aml Second remission patients. They know precisely how their drugs perform - these are the 3 Likely to Be Bidding Now while SLS is Still Massively Undervalued. Ps. does everyone know, SLS a 14 FTE Drug Development co, eliminated the entire direct commercialization team in March of last year - ? the entire Pharma Industry Knows SLS is on the Block and the Clock is ticking.
0 · Reply